-
Atomoxetine, sold
under the
brand name
Strattera among others, is a
selective norepinephrine reuptake inhibitor (sNRI)
medication used to
treat attention...
- (Edronax),
developed as a first-line
therapy for
major depressive disorder.
Atomoxetine (Strattera) is
another potent and
selective NRI
which is also effective...
- non-stimulant medications,
atomoxetine and viloxazine, are
approved by the FDA and in
other countries for the
treatment of ADHD.
Atomoxetine, due to its lack of...
- Non-stimulant
medications with a
specific indication for ADHD
include atomoxetine (Strattera),
viloxazine (Qelbree),
guanfacine (Intuniv), and clonidine...
- the following:
Selective norepinephrine reuptake inhibitors Marketed Atomoxetine (Strattera)
Reboxetine (Edronax, Vestra)
Viloxazine (Qelbree, Vivalan)...
- an extended-release form,
latterly with
comparable effectiveness to
atomoxetine and methylphenidate. Side
effects of
viloxazine include insomnia, headache...
-
studies on
medical treatments are limited, however,
research suggests that
atomoxetine and
lisdexamfetamine may be used to
treat CDS. The
condition was previously...
- effect. For ADHD, the
effectiveness of
methylphenidate is
comparable to
atomoxetine but
modestly lower than amphetamines,
alleviating the
executive functioning...
-
because of the high
dosage required and
potential for
severe side effects.
Atomoxetine (or
reboxetine in Europe) is an
adrenergic reuptake inhibitor which increases...
- brain. The
strong selective norepinephrine reuptake inhibitor (NRI),
atomoxetine (Strattera), has been
approved by the U.S. Food and Drug Administration...
